Bryan R. Haugen, M.D.
Professor of Medicine and Pathology
Head, Division of Endocrinology, Metabolism & Diabetes
Mary Rossick Kern and Jerome H. Kern Chair in Endocrine Neoplasms Research
Since finishing training at the University of Colorado Denver in 1993, Dr. Haugen has been interested in the molecular mechanisms governing thyrotrope function and thyroid neoplasms. He has been studying the cell-specific expression and regulation of TSH including regulation by thyroid hormone and retinoids as well as their respective nuclear receptors. More recently, Dr. Haugen has been studying potential mechanisms involved in thyroid neoplasia and cancer, including the roles of retinoic acid receptors (RAR, RXR), peroxisome proliferator activated receptors (PPAR) and kinase signaling as novel therapeutic targets in advanced thyroid cancer. He has also been involved in proteomic analyses of the thyroid gland and thyroid tumors. Clinically, Dr. Haugen is interested in thyroid and pituitary disorders, particularly novel diagnoses for thyroid neoplasms and therapies for thyroid cancer.
Selected Publications
• Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC and Haugen BR . Deoxyribonucleic Acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endo Metab, 93:4331-41, 2008. PUBMED
• Netea-Maier RT, Hunsucker SW, Hoevenaars B, Helmke SM, Slootweg P, Hermus A, Duncan MW, and Haugen BR . Quantitative and Qualitative Protein Expression Differences Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma. Cancer Research 68:1572-80, 2008 PUBMED
• Golden W, Weber KB, Hernandez TL, Woodmansee WW, Sherman SI, and Haugen BR . Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endo Metab, 92:124-30, 2007 PUBMED
• Cooper DS, Doherty GM, Haugen BR , Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI and Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16:109-142, 2006. PUBMED
• Sharma V, Hays WR, Wood WM, Pugazhenthi U, St. Germain DL, Bianco AC, Krezel W, Chambon P and Haugen BR . Effects of Retinoids on Thyrotrope Function and the Hypothalamic-Pituitary-Thyroid Axis. Endocrinology 147:1438-1551, 2006. PUBMED
• Haugen BR , Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA , and Sharma V. Retinoic acid and retinoid X receptors are differentially expressed expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to natural and synthetic retinoids. J Clin Endo Metab 89:272-280, 2004. PUBMED
• Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, and Haugen BR . Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J Clin Invest 106:73-79, 2000. PUBMED
• Haugen BR , Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham K, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels M, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraib BD, and Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endo Metab . 84:3877-3885, 1999. PUBMED
• Sherman SI, Gopal J, Haugen BR , Chiu AC, Whaley K, Nowlakha P, Truglia JP, Yocum R and Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. New Eng J Med . 340:1075-1079, 1999. PUBMED